Roche, AbbVie forced to slam brakes on myeloma studies of star drug Venclexta after researchers flag higher risk of death
Two heavyweight pharma players today said they’ve been forced to stop recruiting patients for all ongoing studies involving Venclexta (venetoclax) for multiple myeloma. Roche and AbbVie say the drug arm has been linked to a higher rate of death than the control group, prompting the FDA to issue a partial hold ordering them to suspend any new patient recruitment for the blood cancer trials until they can sort out what is happening.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.